Mirum Pharmaceuticals: Q4 Earnings Show Strong Revenue Growth, But Challenges Remain
Mirum Pharmaceuticals (MIRM) recently announced its fourth-quarter 2025 earnings, revealing a significant surge in revenue but also continued losses. The company reported $148.93 million in revenue, a 49.8% increase year-over-year. However, earnings per share (EPS) remained negative at -$0.11, an improvement from the -$0.49 reported in the same quarter last year.
Revenue Beat and Key Sales Figures
The reported revenue exceeded the Zacks Consensus Estimate of $141.27 million, representing a positive surprise of 5.42%. This positive momentum was driven by strong performance in key product sales. Total product sales reached $148.93 million, surpassing the average analyst estimate of $142.62 million.
Specifically, Livmarli, a treatment for progressive familial intrahepatic cholestasis (PFIC), contributed significantly to the revenue increase, generating $106.39 million in sales, exceeding the estimated $98.37 million. Bile Acid Medicines also contributed $42.55 million, closely aligning with the $42.58 million estimate.
EPS Discrepancy and Investor Sentiment
Despite the revenue beat, Mirum experienced an EPS surprise of -650%, with the consensus estimate being $0.02. This discrepancy highlights the ongoing challenges in achieving profitability. However, investor sentiment appears cautiously optimistic, as shares of Mirum Pharmaceuticals have returned +8.3% over the past month, outperforming the Zacks S&P 500 composite’s -0.3% change.
Zacks Perspective and Market Position
Currently, Mirum Pharmaceuticals holds a Zacks Rank #3 (Hold), suggesting it’s expected to perform in line with the broader market in the near term. Analysts suggest that Mirum is uniquely positioned to capitalize on emerging opportunities within the pharmaceutical sector.
The Semiconductor Connection: A Divergent Opportunity
Interestingly, alongside the Mirum Pharmaceuticals report, Zacks Investment Research highlighted a separate investment opportunity in the semiconductor industry. They identified an under-the-radar company specializing in semiconductor products that complement those produced by industry giants like NVIDIA. This company is poised to benefit from the growing demand for Artificial Intelligence, Machine Learning, and the Internet of Things, with the global semiconductor market projected to reach $971 billion by 2028.
Did you know?
The global bile acid market is expected to grow significantly in the coming years, driven by increasing prevalence of liver diseases and advancements in diagnostic techniques.
Frequently Asked Questions
Q: What is Livmarli used for?
A: Livmarli is a treatment for progressive familial intrahepatic cholestasis (PFIC).
Q: What does a Zacks Rank #3 indicate?
A: A Zacks Rank #3 (Hold) suggests the stock is expected to perform in line with the broader market.
Q: What contributed to Mirum’s revenue growth in Q4 2025?
A: Strong sales of Livmarli and Bile Acid Medicines drove the revenue increase.
Q: Is Mirum Pharmaceuticals currently profitable?
A: No, Mirum Pharmaceuticals reported a loss per share of -$0.11 in Q4 2025, although this is an improvement over the previous year.
Explore more investment opportunities and stay informed about market trends. Visit Zacks Investment Research to access in-depth analysis and expert insights.
